Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial

Reuters2026/09/09 06:46

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Elicera Therapeutics will advance ELC-301 into Phase IIa in its CARMA study in B-cell lymphoma, using the highest tested dose.
The trial’s safety panel backed the dose selection with no major safety issues reported in the completed Phase I portion.
Earlier interim results were already presented, showing broad disease control with many patients achieving tumor shrinkage, including some reaching disease-free status.
The company plans to present preliminary Phase I efficacy results for all 12 patients once the last patient completes a one-month assessment.
Phase IIa dosing is expected to start once Sweden’s Medical Products Agency clears the protocol to proceed.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Elicera Therapeutics AB published the original content used to generate this news brief via Cision (Ref. ID: 202609090245BITN____UKPR__EN_20260909-BIT-8070-0) on September 09, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Elicera Therapeutics advances ELC-301 into Phase IIa at highest dose in B-cell lymphoma trial

You may also like

Crypto prices